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Abstract (223/250 words) 
Background: The histopathologic pattern is currently the most important prognostic marker for 
idiopathic interstitial pneumonia (IIP). However, more highly sensitive markers are now required. 
Heat shock protein (HSP) 47, a collagen-specific molecular chaperone, is involved in the processing 
and/or secretion of procollagens, and it has been demonstrated that HSP47 expression is 
significantly higher in the lung specimens of idiopathic UIP than in UIP associated with collagen 
vascular diseases (CVD). However, its expression in nonspecific interstitial pneumonia (NSIP), the 
other common pathological pattern of IIP, has not been well investigated. Therefore, the association 
between lung fibroblast HSP47 expression and prognosis in fibrotic NSIP was evaluated. 
Methods: Surgical lung biopsy specimens of 63 patients [idiopathic fibrotic NSIP = 19, fibrotic 
NSIP associated with CVD = 9, idiopathic UIP = 26, and UIP associated with CVD = 9] were 
reviewed, and a score for lung fibroblast HSP47 expression was assigned. These patients’ clinical 
features and survival were also analyzed. 
Results: There was no significant difference in HSP47 expression between idiopathic fibrotic NSIP 
and fibrotic NSIP associated with CVD. The idiopathic fibrotic NSIP patients with higher HSP47 
expression levels in their lung specimens had a poorer prognosis than patients with lower HSP47 
expression levels. 
Conclusions: The present results suggest that lung fibroblast HSP47 expression may be a useful 
new prognostic marker for idiopathic fibrotic nonspecific interstitial pneumonia. 
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Introduction 
Idiopathic interstitial pneumonia (IIP) is currently classified into seven 
clinico-radiologic-pathologic entities, which differ not only in pathology but also in their 
clinical features.1 Of these, the majority of IIP cases are nonspecific interstitial pneumonia 
(NSIP) and usual interstitial pneumonia (UIP). Idiopathic NSIP (I-NSIP) has been reported 
to have a more favorable prognosis and a better response to steroids than idiopathic 
pulmonary fibrosis (idiopathic UIP; I-UIP),2-5 suggesting that the pathogenesis of I-NSIP is 
different from that of I-UIP. In addition, whether I-NSIP is a distinct entity remains 
controversial because the reported survival rates of I-NSIP patients are variable,2, 4-8 and 
NSIP has a close relationship with collagen vascular disease (CVD).7, 9 Though the most 
common pathological patterns in interstitial pneumonia associated with CVD (CVD-IP) are 
also NSIP and UIP, patients with CVD-IP have been reported to have a better prognosis 
than patients with IIP.4, 10 In this context, Flaherty et al10 reported that patients with 
CVD-associated UIP (CVD-UIP) have fewer fibroblastic foci in the lung than those with 
I-UIP. However, the phenotypic difference in lung cells between these diseases and its 
association with the prognosis are poorly understood. 
Heat shock protein 47 (HSP47), localized in the endoplasmic reticulum, is involved in 
the synthesis/assembly of various collagens as a collagen-specific molecular chaperone. 
HSP47 expression is regulated in parallel with collagen expression, and HSP47 
overexpression leads to production of excess extracellular matrix, which then results in 
various fibrotic diseases.11-13 We have previously reported that HSP47 was strongly 
expressed in the lung cells of patients with I-UIP,14 and that the HSP47 expression level in 
lung cells was significantly higher in I-UIP than in CVD-UIP.13 These findings suggest that 
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I-UIP and CVD-UIP have different fibrotic pathways, and that HSP47 expression may be a 
good predictor of prognosis in patients with fibrotic IP. 
Therefore, in this study, the expression of HSP47 in lung fibroblasts was examined in 
fibrotic IP, including fibrotic I-NSIP (I-fNSIP), fibrotic CVD-NSIP (CVD-fNSIP), I-UIP 
and CVD-UIP, to evaluate the usefulness of HSP47 as a prognostic marker.
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Materials and Methods 
Study populations 
The subjects of this study were patients who attended the Nagasaki University Hospital 
between 1991 and 2007. The study protocol was approved by the human ethics review 
committees of Nagasaki University School of Medicine, and written, informed consent was 
obtained from each patient. The subjects included 63 patients (45 with IIP and 18 with 
CVD-IP) diagnosed based on surgical lung biopsy as fNSIP pattern (19 with I-fNSIP, 9 
with CVD-fNSIP) or UIP pattern (26 with I-UIP, and 9 with CVD-UIP) according to the 
consensus criteria of the American Thoracic Society/European Respiratory Society.1 None 
of the patients were pathologically diagnosed as having cellular-NSIP. The associated 
diagnoses in the CVD-fNSIP patients were rheumatoid arthritis (n=1), mixed connective 
tissue disease (MCTD; n = 1), systemic sclerosis (SSc; n = 2), dermatomyositis (DM; n = 
4), and DM + Sjögren syndrome (SjS; n=1). The associated diagnoses in the CVD-UIP 
patients were MCTD (n = 1), SjS (n = 3), SSc (n = 3), DM + SjS (n=1), and SSc + SjS 
(n=1). The mean follow-up period after the surgical lung biopsy was 69.6 ± 5.8 (range: 
1-195) months. None of the patients had received steroids or other immunosuppressive 
therapies when the surgical lung biopsy was performed. Patients’ data before surgical lung 
biopsy, including age, smoking history, results of pulmonary function tests, arterial blood 
gas analysis, and bronchoalveolar lavage fluid (BALF) findings, were collected from the 
hospital medical records (Table 1,2). Control lung tissues were obtained from normal areas 
of surgically resected lung specimens from patients with lung cancer (4 men and 6 women; 




The primary antibodies used for the immunohistochemical study included anti-HSP47 
(Biotechnologies Corp., Victoria, Canada). Negative control studies were performed using 




Immunohistochemistry was performed with the conventional avidin-biotin-peroxidase 
histochemical technique using the Vecstain Elite ABC Kit (Vector Laboratories, 
Burlingame, CA, USA). Briefly, sequential paraffin sections (4 µm thick) were 
deparaffinized with toluene and rinsed thoroughly with ethanol. The sections were then 
soaked in 0.3% H2O2 with absolute methanol for 20 minutes at room temperature to 
inactivate the endogenous peroxidase activity. They were incubated with blocking serum 
for 30 minutes, and then covered with primary antibodies at 4°C overnight. After washing 
in phosphate-buffered saline, the sections were processed further using the kits according to 
the instructions provided by the manufacturer, and then developed with 
3,3'-diaminobenzidine and H2O2, followed by Mayer's hematoxylin staining method. 
 
Pathologic assessment 
The staining intensity and distribution of HSP47 in fibroblasts in active fibrotic areas 
(fibroblastic foci in UIP cases; alveolar septal interstitium expanded by fibrosis and 
intra-alveolar organizing fibrosis in fNSIP cases) were scored semi-quantitatively using a 
grading system of 0 to 3 (0 = negative; 1 = weak; 2 = moderate; 3 = strong). The 
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immunohistochemical score for each patient was calculated by averaging the score of each 
lobe. Histological sections were assessed independently, twice by each of two observers, 
and then analyzed statistically. Analysis of interobserver and intraobserver variability 
showed that the results were reproducible. 
Statistical analysis 
All values are described as mean ± standard error. Differences in categorical data 
between two groups were assessed by Fisher’s exact probability test for data with two 
categories and by chi-square test for data with three or more categories. Differences in 
continuous data between two groups were assessed using the Wilcoxon rank-sum test, and 
differences in continuous data among three groups were assessed using the Kruskal-Wallis 
test. In addition, multivariate Cox regression analysis was used to examine the relationships 
between the presence/absence of idiopathic UIP and CVD-UIP and other variables. The 
overall survival experience for each group was estimated using Kaplan-Meier curves. The 
log-rank test was used to compare survival between two groups. Statistical significance was 
defined by a p value of less than 0.05. All data were analyzed using statistical software 




Patient Characteristics and Survival 
The I-fNSIP and CVD-fNSIP groups were both female-dominant and in their 
mid-fifties (Table 1). The percentage of neutrophils in BALF was slightly greater in 
CVD-fNSIP than in I-fNSIP. Figure 1 shows the comparison of the survival curves of the 
I-fNSIP, CVD-fNSIP, I-UIP, and CVD-UIP groups. The 5-year survival rates were: 78.2% 
in the I-fNSIP group; 77.8% in the CVD-fNSIP group; 51% in the I-UIP group; and 100% 
in the CVD-UIP group. Using the log-rank test, no significant difference in survival was 
found between the I-fNSIP and CVD-fNSIP groups (p = 0.903); the I-UIP group had the 
worst prognosis, which was significantly different from that of the CVD-UIP group (p = 
0.015). The age of the patients was significantly different between the idiopathic UIP and 
CVD-UIP groups (p=0.0255). After accounting for the age difference using multivariate 
Cox regression analysis, the prognoses of the I-UIP and CVD-UIP subgroups were still 
different, though the difference was not significant (p=0.07). There was no association 
between survival and clinical features such as serum markers, results of pulmonary function 
tests, and BALF findings (data not shown). 
 
Results of Pathologic Assessment and Their Association with Clinical Findings and 
Survival 
Representative examples of immunohistochemical staining for HSP47 in patients with 
I-fNSIP are shown in Figure 2. In fNSIP cases, unlike fibroblastic foci in UIP cases, lesions 
with active fibroblast proliferation were analyzed. The HSP47 scores in lung fibroblasts 
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were evaluated in all patients and controls (Figure 2). A negative control study using 
nonspecific immunoglobulin-G revealed no positive cells (data not shown). 
 
HSP47 expression was significantly higher in all patient groups than in controls (vs. 
I-fNSIP, p = 0.0001; vs. CVD-fNSIP, 0.0017; vs. I-UIP, p<0.0001; vs. CVD-UIP, p = 
0.0065) (Figure 3). Furthermore, the I-UIP group had a significantly higher expression of 
HSP47 than the CVD-UIP group (p = 0.0395). No significant difference was found 
between the I-fNSIP and CVD-fNSIP groups (p = 0.335). The associations between the 
HSP47 score and clinical features and laboratory data, including the pulmonary function 
test, PaO2/FiO2 ratio and BALF findings, were also evaluated, but no associations were 
identified (data not shown). Figure 4 shows the survival curves of the I-fNSIP cases (A) 
and the I-UIP (B) groups, divided into two subgroups based on the average fibroblast 
HSP47 scores (1.19 and 1.36, respectively). In the I-fNSIP group, cases with HSP47 scores 
higher than the average value appeared to have a worse prognosis than those with HSP47 
scores lower than the average value, though the p value was not calculable. In contrast, in 
the I-UIP group, there was no significant association between the HSP47 score and 
prognosis (p = 0.2632). In the CVD-fNSIP and CVD-UIP groups, there was no significant 




The histopathologic pattern of UIP is well-characterized, with the cardinal feature being 
the patchy distribution of temporally heterogeneous fibrosis, comprising areas of 
established fibrosis with adjacent foci of fibroblastic proliferation (so-called fibroblastic 
foci). Recent studies have emphasized the importance of the fibroblastic focus as a 
manifestation of ongoing lung injury in patients with established fibrosis.15-20 A number of 
investigators have stressed the prognostic value of quantifying fibroblastic foci in patients 
with idiopathic interstitial pneumonia.19, 20 Furthermore, a previous study showed that 
patients with CVD-UIP have fewer fibroblastic foci and better prognosis than patients with 
I-UIP.10 In I-NSIP, which exhibits a more favorable response to corticosteroids and has a 
better prognosis than I-UIP,8, 21-24 fibroblastic foci with dense fibrosis are inconspicuous or 
absent.1 Thus, fibroblasts are believed to play an important role in the progression of 
chronic pulmonary fibrosis. However, previous studies did not fully elucidate the 
phenotypic differences in fibroblasts among I-UIP, CVD-UIP, I-NSIP, and CVD-NSIP. 
In the present study, it was confirmed that expression of HSP47 in lung fibroblasts was 
higher in I-UIP patients than in CVD-UIP patients, as previously reported.13 In this study, 
we reported the new finding that there was no significant difference in fibroblast HSP47 
expression between patients with I-fNSIP and those with CVD-fNSIP. It is quite interesting 
that our findings suggest that I-UIP and CVD-UIP have different fibrotic pathways, while 
I-fNSIP and CVD-fNSIP might have similar fibrotic processes. This is consistent with the 
recent idea that I-NSIP and CVD-NSIP might be similar pathophysiological entities. Some 
authors have reported that the prognoses of I-NSIP and CVD-NSIP patients were similar,4, 
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25 and that it is very difficult to distinguish I-NSIP from NSIP associated with underlying 
diseases.26 In the present study, we also demonstrated that the I-fNSIP and CVD-fNSIP 
groups had almost the same prognosis (5-year survival, 77.5% and 77.8%, respectively), 
and their lung fibroblast HSP47 expression was also similar. There is a clinical condition 
called undifferentiated connective tissue disease (UCTD) characterized by the presence of 
signs and symptoms suggestive of a systemic autoimmune disease without satisfying the 
criteria for connective tissue diseases.27 It has been recently hypothesized that I-NSIP is an 
autoimmune disease that is the lung manifestation of UCTD,7 or that NSIP might be the 
first clinical presentation of various CVDs.9 Still, a recent report stated that I-NSIP was a 
distinct clinical entity with a very good prognosis.5 Thus, the ultimate goal now is to 
determine what NSIP is. 
Jegal et al demonstrated that decreased initial forced vital capacity and diffusing capacity 
of lung for carbon monoxide, increased age, male sex, a lower resting PaO2, and 
deteriorated forced vital capacity at 6 months, in addition to the pathologic pattern of UIP, 
were all associated with increased mortality among 179 fibrotic IP patients.3 In addition to 
these, the present study showed that higher fibroblast HSP47 expression was significantly 
associated with poor mortality in I-fNSIP patients. As the expression and synthesis of 
HSP47 closely correlates with that of collagens in various cell lines and tissues of fibrosis 
models,13, 28-31 higher HSP47 expression reflects advanced collagen synthesis and stronger 
fibrotic change in the involved lung, and this might correlate well with poor prognosis in 
these diseases. However, there was no association between fibroblast expression of HSP47 
and prognosis in I-UIP patients. These findings imply that the association between HSP47 
expression and prognosis differs somewhat between I-UIP and I-fNSIP. The NSIP pattern 
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encompasses a broad spectrum of histologic features with varying degrees of alveolar wall 
inflammation or fibrosis.1 Of the types of IIP, the histologic features of NSIP do not fit the 
histologic pattern of UIP, organizing pneumonia, diffuse alveolar damage, desquamative 
interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, or 
lymphoid interstitial pneumonia. In contrast to UIP, it is uncertain whether NSIP is an 
independent clinical entity. In view of the variable pathology, response to treatment, and 
prognosis, further subclassification is warranted. The expression of HSP47 might be useful 
for further subclassification of NSIP. However, this study has limitations, in that it included 
only a small number of patients and was retrospective. Furthermore, the comparisons were 
not adjusted for other factors. Various selection biases (patient selection, selection of 
fragments in surgical lung biopsy, and selection of therapy for each patient) affect the 
results in this study. Thus, well-planned prospective studies using a large number of 
patients are required to determine the role of HSP47 as a prognostic factor in interstitial 
pneumonias. 
In conclusion, we have shown that there was no significant difference in fibroblast 
HSP47 expression between patients with I-fNSIP and those with CVD-fNSIP. We also 
have shown that higher fibroblast HSP47 expression was significantly associated with poor 
mortality in I-fNSIP patients. Our findings imply that I-fNSIP and CVD-fNSIP might have 
similar fibrotic processes, and that HSP47 might be a prognostic marker for I-NSIP. Further 
studies involving a large number of patients are required to determine the prognostic and 
therapeutic values of HSP47 expression. 
 13
Acknowledgements 
The authors would like to thank Mr. Atsushi Yokoyama for his excellent technical 
assistance, Dr. Masanori Kitaichi (Department of Laboratory Medicine and Pathology, 
NHO Kinki-Chuo Chest Medical Center) for his valuable advice regarding pathological 
diagnoses, and Dr. Mariko Mine (Division of Scientific Data Registry, Atomic Bomb 
Disease Institute, Nagasaki University Graduate School of Biomedical Sciences) for her 
valuable advice regarding the statistical analysis. 
 
Conflict of Interest 




1. American Thoracic Society/European Respiratory Society International 
Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. 
This joint statement of the American Thoracic Society (ATS), and the European 
Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and 
by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 
2002;165:277-304. 
2. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: 
the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 
2003;168:531-7. 
3. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than 
pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 
2005;171:639-44. 
4. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic 
versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 
2007;175:705-11. 
5. Travis WD, Hunninghake G, King TE, Jr., et al. Idiopathic nonspecific interstitial 
pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care 
Med 2008;177:1338-47. 
6. Nagai S, Handa T, Tabuena R, Kitaichi M, and Izumi T. Nonspecific interstitial 
pneumonia: a real clinical entity? Clin Chest Med 2004;25:705-15. 
7. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: 
 15
lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care 
Med 2007;176:691-7. 
8. Nicholson AG, Colby TV, du Bois RM, Hansell DM, and Wells AU. The prognostic 
significance of the histologic pattern of interstitial pneumonia in patients presenting 
with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 
2000;162:2213-7. 
9. Sato T, Fujita J, Yamadori I, et al. Non-specific interstitial pneumonia as the first 
clinical presentation of various collagen vascular disorders. Rheumatol Int 
2006;26:551-5. 
10. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial 
pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 
2003;167:1410-5. 
11. Shioshita K, Miyazaki M, Ozono Y, et al. Expression of heat shock proteins 47 and 70 
in the peritoneum of patients on continuous ambulatory peritoneal dialysis. Kidney Int 
2000;57:619-31. 
12. Nagata K. [Therapeutic strategy for fibrotic diseases by regulating the expression of 
collagen-specific molecular chaperone HSP47]. Nippon Yakurigaku Zasshi 
2003;121:4-14. 
13. Kakugawa T, Mukae H, Hayashi T, et al. Expression of HSP47 in usual interstitial 
pneumonia and nonspecific interstitial pneumonia. Respir Res 2005;6:57. 
14. Iwashita T, Kadota J, Naito S, et al. Involvement of collagen-binding heat shock protein 
47 and procollagen type I synthesis in idiopathic pulmonary fibrosis: contribution of 
type II pneumocytes to fibrosis. Hum Pathol 2000;31:1498-505. 
 16
15. Kuhn C, and McDonald JA. The roles of the myofibroblast in idiopathic pulmonary 
fibrosis. Ultrastructural and immunohistochemical features of sites of active 
extracellular matrix synthesis. Am J Pathol 1991;138:1257-65. 
16. Selman M, King TE, and Pardo A. Idiopathic pulmonary fibrosis: prevailing and 
evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern 
Med 2001;134:136-51. 
17. Katzenstein AL, and Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of 
pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15. 
18. Cooper JA, Jr. Pulmonary fibrosis: pathways are slowly coming into light. Am J Respir 
Cell Mol Biol 2000;22:520-3. 
19. King TE, Jr., Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship 
between histopathologic features and mortality. Am J Respir Crit Care Med 
2001;164:1025-32. 
20. Nicholson AG, Fulford LG, Colby TV, et al. The relationship between individual 
histologic features and disease progression in idiopathic pulmonary fibrosis. Am J 
Respir Crit Care Med 2002;166:173-7. 
21. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic 
subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 
1998;157:199-203. 
22. Travis WD, Matsui K, Moss J, and Ferrans VJ. Idiopathic nonspecific interstitial 
pneumonia: prognostic significance of cellular and fibrosing patterns: survival 
comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. 
Am J Surg Pathol 2000;24:19-33. 
 17
23. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific 
interstitial pneumonia is associated with a better prognosis than usual interstitial 
pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 
1999;160:899-905. 
24. Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological 
classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-83. 
25. Nakamura Y, Chida K, Suda T, et al. Nonspecific interstitial pneumonia in collagen 
vascular diseases: comparison of the clinical characteristics and prognostic significance 
with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:235-41. 
26. Fujita J, Ohtsuki Y, Yoshinouchi T, et al. Idiopathic non-specific interstitial pneumonia: 
as an "autoimmune interstitial pneumonia". Respir Med 2005;99:234-40. 
27. Mosca M, Tani C, Neri C, Baldini C, and Bombardieri S. Undifferentiated connective 
tissue diseases (UCTD). Autoimmun Rev 2006;6:1-4. 
28. Masuda H, Fukumoto M, Hirayoshi K, and Nagata K. Coexpression of the 
collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen 
genes in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1994;94:2481-8. 
29. Pan H, and Halper J. Regulation of heat shock protein 47 and type I procollagen 
expression in avian tendon cells. Cell Tissue Res 2003;311:373-82. 
30. Yoshioka S, Mukae H, Ishii H, et al. Alpha-defensin enhances expression of HSP47 and 
collagen-1 in human lung fibroblasts. Life Sci 2007;80:1839-45. 
31. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of 





Comparison of the survival curves of all subject groups. 
 
Figure 2 
Immunohistochemical staining for HSP47 of surgical lung biopsy specimens taken from 
patients with idiopathic fibrotic NSIP. Fibroblast HSP47 score: a = 0 (negative), b = 1 
(weak), c = 2 (moderate), d = 3 (strong). Scale bar = 500 µm. 
 
Figure 3 
Box-and-whisker plots of the HSP47 scores in lung fibroblasts in patients with 
idiopathic-fNSIP, CVD-fNSIP, idiopathic-UIP, and CVD-UIP. 
*p<0.01, compared with control. The boxes represent the 25th to 75th percentiles, the solid 
lines within the boxes show the median values, the whiskers are the 10th and 90th 
percentiles. CVD = collagen vascular disease; HSP47 = heat shock protein 47; fNSIP = 
fibrotic nonspecific interstitial pneumonia; UIP = usual interstitial pneumonia. 
 
Figure 4 
The survival curves of the idiopathic-fibrotic NSIP (A) and idiopathic-UIP (B) groups, 




Collagen vascular disease 
Fibrotic interstitial pneumonia 
Fibrotic nonspecific interstitial pneumonia 
Heat shock protein 47 
Usual interstitial pneumonia 
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Abbreviation List 
BALF: Bronchoalveolar lavage fluid 
CVD: collagen vascular disease 
DM: dermatomyositis 
I-fNSIP: idiopathic fibrotic nonspecific interstitial pneumonia 
HSP: heat shock protein 
IIP: idiopathic interstitial pneumonia 
IPF: idiopathic pulmonary fibrosis 
MCTD: mixed connective tissue diseases 
SjS: Sjögren syndrome 
SSc: systemic sclerosis 
I-UIP: idiopathic usual interstitial pneumonia 
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